Syros Pharmaceuticals

Company profile

About

Syros Pharmaceuticals (NASDAQ:SYRS) is a biopharmaceutical company focused on the development of treatments for cancer and diseases caused by gene dysregulation. The company leverages its proprietary gene control platform to systematically identify and target the regulatory genes that are the root cause of these serious illnesses. With a commitment to transforming the lives of patients, Syros is advancing a diverse pipeline of small molecules that are designed to control the expression of genes implicated in disease onset and progression. Their objective is to achieve a new wave of medicines that precisely control the expression of genes critical for the health of individuals with conditions that presently have limited treatment options.

Snapshot

2011Year founded

117Employees

Massachusetts, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

United States

Products and/or services of Syros Pharmaceuticals

Tamibarotene, a potent and selective retinoid acid receptor alpha agonist for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
SY-5609, a highly selective CDK7 inhibitor, targeting a range of solid tumors including breast, colorectal, and lung cancers.
SY-2101, a novel oral form of arsenic trioxide aimed at improving treatment experience and outcomes in patients with AML.
Partnership with Global Blood Therapeutics for the discovery, development, and commercialization of novel therapies for beta thalassemia and sickle cell disease.
Collaboration with Incyte to identify and develop novel therapies targeting the bromodomain and extra-terminal (BET) family of proteins for the treatment of cancer and other diseases.
Development of a proprietary gene control platform that aims to systematically and efficiently analyze the regulatory genome for drug development.